The ONTARGET Study

Researchers are expecting that combined drug therapies will help reduce heart disease-associated mortality. The ONTARGET trial looked at an angiotensin receptor blocker and ACE inhibitor (telmisartan and ramipril), traditionally anti-hypertensive drugs, in the treatment of cardiovascular disease in the absence of heart failure.

Read more in my article at Suite101.

No comments: